



INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A SYSTEMIC REVIEW ON THE IMPACT OF VITAMIN B6 DEFICIENCY ON THE SEVERITY OF DIABETIC PERIPHERAL NEUROPATHY

ADHITHYA A^{1*}, SOUMYA R V², ANJANA U J³, PRASOBH G R⁴,

NITHIN MANOHAR⁵, ADITHYA SATHEESH KUMAR¹, SREE LAKSHMI D R¹,

VARSHA VINCENT¹

- 1.Fifth Year Doctor of Pharmacy Students, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India
- 2.Associate Professor, Department of Pharmacy Practice, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India
- 3.Assistant Professor, Department of Pharmacy Practice, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India
- 4.Principal, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India
- 5.Proffessor, HOD, Department of Pharmacy Practice, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India

ABSTRACT

Diabetic peripheral neuropathy is the commonest cause of neuropathy worldwide and the severity of neuropathic pain increases with increase in the duration of diabetes. Vitamin B6 is a water-soluble vitamin that is present in foods such as pork, poultry, oats, bananas, dark leafy green vegetables and is accessible in many dietary supplements. The deficiency of Vitamin B6 is considered as a risk factor for developing peripheral neuropathy. Pyridoxine strongly contributes to the proper functioning of the nervous system by facilitating neurotransmitters and myelin synthesis. Studies show that there is a decrease in serum Pyridoxal 5'Phosphate levels in diabetic patients when compared with healthy population which may contribute to glucose intolerance. Vitamin B6 supplements are used in management of diabetic neuropathy for its anti-oxidant property and which had indeed helped in reduction of painful symptoms of neuropathy. Vitamin B6 when taken in higher doses greater than daily requirement will causes neuronal damage as well.

KEYWORDS: Diabetes, VitaminB6, Neuropathy, Pyridoxine.

INTRODUCTION

Diabetes is one of the leading metabolic disorders of hyperglycemia which can be due to decreased insulin secretion, increased glucose production or decreased glucose utilization. One of the severe complications of diabetes is Neuropathy which is considered to be related to duration and severity of hyperglycemia¹. More than 60% of patients with a history of diabetes greater than 15 years are at risk of developing neuropathic pain. Diabetic neuropathy can be defined as the presence of symptoms or signs of peripheral nerve dysfunction resulting in severe pain in lower and upper limbs². Neuropathic pain generally begins in the toes bilaterally and then proceeds to feet and legs. After establishing in the lower limb completely the upper limbs are affected. Currently the treatment for painful neuropathy is for symptomatic relief which may not alter the disease process. The most commonly prescribed drug for neuropathic pain includes gabapentin, pregabalin and tricyclic antidepressants³.

PATHOGENESIS OF DIABETIC NEUROPATHY

The pathogenesis of diabetic neuropathy is multifactorial and it differs between T1DM and T2DM. Increased glucose position in the blood for longer duration can affect the nerves in several ways.

Studies shows that there are four applicable mechanisms that show how hyperglycemia causes DPN in cases^{4,5,6}.

Increased Polyol Pathway Flux;

The polyol pathway thesis states the fact that hyperglycemia convinced increased flux through polyol pathway via enzyme aldose reductase performing in accumulation of sorbitol in nerves and therefore reducing the nerve conduction velocity⁷.

Activation of Protein Kinase- C(PKC) Pathway

The functions of other proteins are controlled by the co enzyme protein kinase. Neuronal death occurs after transubstantiating growth factor B leading to vascular occlusion is a common medium for neuropathy and vascular disease⁸.

Increased Advanced Glycated End- products conformation

Advanced Glycated End- products are formed as a result of hyperglycemia through non-enzymatic glycation of proteins therefore leading to the conformation of covalent bonds between proteins or lipids leading to intra and extracellular crosslinking and aggregation leading to injurious effect on nerves⁹.

Increased Hexosamine Pathway Flux

In this pathway neuroinflammation associated with DPN occurs which is due to accumulation of extracellular matrix with hyperglycemia¹⁰.

RISK FACTORS

The major threat factors for DPN include hyperglycemia, diabetes duration and insulin resistance followed by dyslipidemia and hypertension. Other threat factors include obesity, smoking and exposure to AGEs through food intake¹¹.

DIAGNOSIS

The differential diagnosis of neuropathy is a very crucial step. According to severity defined grades of DPN were defined by Toronto Diabetic Neuropathy Expert Group as^{12,13}.

- Grade 0: no abnormality of nerve conduction
- Grade 1a: abnormality of nerve conduction without symptoms or signs
- Grade 1b: nerve conduction abnormality of stage 1a plus neurologic signs typical of DSPN, but without neuropathy symptoms
- Grade 2a: nerve conduction abnormality of stage 1a with or without signs (but if present, <2b) and with typical neuropathic symptoms
- Grade 2b: nerve conduction abnormality of stage 1a, a moderate degree of weakness (i.e., 50%) of ankle dorsiflexion with or without neuropathy symptoms.

ROLE OF VITAMIN B6 IN DIABETES

Vitamin B6 is a water-soluble vitamin and is metabolized and excreted fastly from the body thereby resulting in a very less toxicity. Vitamin B6 is a main compound for regulating the metabolizing of glucose, lipids, amino acids and various neurotransmitters¹⁴. There are mainly 6 common forms of vitaminB6 pyridoxine (PN), pyridoxal (PL), pyridoxamine (PM) and 5' phosphate derivatives. The active form of vitamin B6 is pyridoxal 5'-phosphate which act as a coenzyme for more than 150 distinct enzymatic reactions of metabolism¹⁵⁻¹⁷.

The microvascular hypothesis of Diabetic neuropathy states that high homocysteine, nitric acid and reduced levels of folic acid mainly occurs due to capillary membrane thickening and hypoxic changes and an important co factor for this metabolism is pyridoxine¹⁸. The recommended daily amount of dietary vitamin B6 is between 1.6-2mg/day for adults¹⁹. Vitamin B6 boosts the health of nerves and is essential in maintaining the proper functioning of nervous system. A deficiency in vitamin B6 can cause a stress in the nervous system and cause nerve damage.

Low level of pyridoxine can cause increase in homocysteine levels leading to damage inside the arteries²⁰. In case of excessive oxidative stress there is increase in level of advanced glycated end products which is considered as one of the main reasons for developing DPN. Plasma pyridoxal 5'-phosphate concentration (PLP) is the best technique to measure the levels of vitamin B6. A person is said to have vitamin B6 deficiency if his/her PLP plasma concentration is lesser than 30nmol/L²¹.

Most of the complications of diabetics occurs due to the formation of Advanced Glycated End products (AGEs). Glycating products also produces AGEs by reacting with amino acids of proteins. These AGEs will accumulate in the body and causes inflammation as well as destroy normal structure of blood vessels resulting in vascular problems^{22,23}.

Various studies shows that Vitamin B6 plays a major role in one of the AGE pathways by blocking 3-deoxyglucosone and thus preventing the binding to proteins²⁴. Studies also shows that vitamin B6 administration had significantly reduced neuropathy and also slowed the course of diabetic nephropathy. It is believed that the antioxidant properties of vitamin B6 has greater impact on diabetic problems^{25,26}.

DISCUSSION

The study reported that pyridoxine deficiency is prevalent among patients with diabetic neuropathy. About 51.8% of patients have vitamin B6 deficiency. There also exist a relationship that fasting blood sugar levels and glycosylated hemoglobin, pyridoxine deficiency can cause impaired glucose tolerance^{27,28}.

In the conversion of tryptophan to nicotinic acid pyridoxal 5'-phosphate act as a co enzyme. If this conversion is interrupted various intermediate products will be formed that have the potential to interact with biological insulin leading to insulin resistance²⁹. The lower levels of vitamin B6 in T2DM were thought to be because of poor reabsorption processes³⁰.

Various studies discovered that the plasma PLP levels in diabetic patients is significantly less when compared with healthy individuals³¹. The decrease in the PLP levels could be because of an increase in demand by the PLP-dependent enzymes, immune cell proliferation or mobilization of the co enzyme the site of inflammation³². Our study shows that there is a direct significant relationship of pyridoxine and nerve conduction velocity. Also, pyridoxine cannot be synthesized by human on their own hence they are dependent on various sources for pyridoxine³³.

CONCLUSION

Vitamin B6 is a water-soluble vitamin whose deficiency can worsen diabetic complication. About 51.8% of patients with diabetes have vitamin B6 deficiency. There also exist a strong relationship between pyridoxine deficiency and glucose intolerance. Vitamin B6 supplements with its anti-oxidant properties are helpful in treating the symptoms of painful diabetic neuropathy.

ABBREVIATIONS

DM: Diabetes Mellitus

DPN: Diabetic Peripheral Neuropathy

PLP: Pyridoxal 5'-phosphate

AGE: Advanced Glycated End product

T2DM: Type 2 Diabetes Mellitus

FBS: Fasting Blood Sugar

DSPN: Diabetes Sensory Motor Neuropathy

REFERENCES

1. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, LeBel AA, Levy RM, Mackey SC. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. In Mayo Clinic Proceedings 2010 Mar 1 (Vol. 85, No. 3, pp. S3-S14).
2. Banu P, Mondal S, Biswas A, Naser SM, Niyogi M. Prescribing trends in diabetic neuropathy at a tertiary care hospital. Asian Journal of Medical Sciences. 2018 Aug 31;9(5):8-11.
3. Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nature Reviews Endocrinology. 2021 Jul;17(7):400-20.
4. Perez-Matos MC, Morales-Alvarez MC, Mendivil CO. Lipids: a suitable therapeutic target in diabetic neuropathy? Journal of diabetes research. 2017;2017
5. Greig M, Tesfaye S, Selvarajah D, Wilkinson ID. Insights into the pathogenesis and treatment of painful diabetic neuropathy. Handbook of Clinical Neurology. 2014 Jan 1; 126:559-78.
6. Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropathy. Bmj. 2014 May 6;348.
7. Llewelyn JG, Thomas PK, Fonseca V, King RH, Dandona P. Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta neuropathologica. 72:157-63.
8. Shakeel M. Recent advances in understanding the role of oxidative stress in diabetic neuropathy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2015 Oct 1;9(4):373-8.
9. Chillelli NC, Burlina S, Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycooxidation-centric" point of view. Nutrition, Metabolism and Cardiovascular Diseases. 2013 Oct 1;23(10):913-9.
10. Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A. Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. International journal of endocrinology. 2014 Oct;2014.
11. Papanas N, Ziegler D. Risk factors and comorbidities in diabetic neuropathy: an update 2015. The review of diabetic studies: RDS. 2015;12(1-2):48.
12. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes care. 2010 Oct 1;33(10):2285-93.
13. Amara F, Hafez S, Orabi A, El Etriby A, Abdel Rahim AA, Zakaria E, Koura F, Talaat FM, Gawish H, Attia I, Abdel Aziz MF. Review of diabetic polyneuropathy: pathogenesis, diagnosis and management according to the consensus of Egyptian experts. Current diabetes reviews. 2019 Aug 1;15(4):340-5.

14. Mascolo E, Verni F. Vitamin B6 and diabetes: relationship and molecular mechanisms. *International journal of molecular sciences*. 2020 May 23;21(10):3669.
15. Mooney S, Leuendorf JE, Hendrickson C, Hellmann H. Vitamin B6: a long-known compound of surprising complexity. *Molecules*. 2009 Jan 12;14(1):329-51
16. Percudani R, Peracchi A. A genomic overview of pyridoxal-phosphate-dependent enzymes. *EMBO reports*. 2003 Sep;4(9):850-4.
17. Di Salvo ML, Contestabile R, Safo MK. Vitamin B6 salvage enzymes: mechanism, structure and regulation. *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics*. 2011 Nov 1;1814(11):1597-608.
18. Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: distinct or continuum? *Indian journal of endocrinology and metabolism*. 2016 Jul;20(4):546.
19. Calderon-Ospina CA, Nava-Mesa MO, Paez-Hurtado AM. Update on safety profiles of vitamins B1, B6, and B12: a narrative review. *Therapeutics and clinical ri*
20. Kraus JP, Hašek J, Kožich V, Collard R, Venezia S, Janošíková B, Wang J, Stabler SP, Allen RH, Jakobs C, Finn CT. Cystathionine γ -lyase: Clinical, metabolic, genetic, and structural studies. *Molecular genetics and metabolism*. 2009 Aug 1;97(4):250-9
21. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. *International journal of molecular sciences*. 2018 Oct 26;19(11):3342.
22. Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: Mechanisms and perspectives. *Biomolecules*. 2022 Apr 4;12(4):54
23. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. *Circulation*. 2006 Aug 8;114(6):597-605.
24. Marques CM, Nunes EA, Lago L, Pedron CN, Manieri TM, Sato RH, Junior VX, Cerchiaro G. Generation of Advanced Glycation End-Products (AGEs) by glycooxidation mediated by copper and ROS in a human serum albumin (HSA) model peptide: reaction mechanism and damage in motor neuron cells. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*. 2017 Dec 1; 824:42-51.
25. Nix WA, Zirwes R, Bangert V, Kaiser RP, Schilling M, Hostalek U, Obeid R. Vitamin B status in patients with type 2 diabetes mellitus with and without incipient nephropathy. *Diabetes research and clinical practice*. 2015 Jan 1;107(1):157-65.
26. Cohen KL, Gorecki GA, Silverstein SB, Ebersole JS, Solomon LR. Effect of pyridoxine (vitamin B6) on diabetic patients with peripheral neuropathy. *Journal of the American Podiatry Association*
27. Oxenkrug G. Insulin resistance and dysregulation of tryptophan–kynurenine and kynurenine–nicotinamide adenine dinucleotide metabolic pathways. *Molecular neurobiology*. 2013 Oct; 48:294-301.
28. Khobrani M, Kandasamy G, Vasudevan R, Alhossan A, Puvvada RC, Devanandan P, Dhurke R, Naredla M. Impact of vitamin B6 deficiency on the severity of diabetic peripheral neuropathy—A cross sectional study. *Saudi Pharma*
29. Moreno-Navarrete JM, Jove M, Ortega F, Xifra G, Ricart W, Obis E, Pamplona R, Portero-Otin M, Fernández-Real JM. Metabolomics uncovers the role of adipose tissue PDXK in adipogenesis and systemic insulin sensitivity. *Diabetologia*. 2016 Apr;59(4):822-32. *ceutical Journal*. 2023 May 1;31(5):655-8.
30. Iwakawa H, Nakamura Y, Fukui T, Fukuwatari T, Ugi S, Maegawa H, Doi Y, Shibata K. Concentrations of water-soluble vitamins in blood and urinary excretion in patients with diabetes mellitus. *Nutrition and Metabolic Insights*. 2016 Jan;9: NMI-S40595.
31. Satyanarayana A, Balakrishna N, Pitla S, Reddy PY, Mudili S, Lopamudra P, Suryanarayana P, Viswanath K, Ayyagari R, Reddy GB. Status of B-vitamins and homocysteine in diabetic retinopathy: association with vitamin-B12 deficiency and hyperhomocysteinemia. *PloS one*. 2011 Nov 1;6(11): e26747.
32. Paul L, Ueland PM, Selhub J. Mechanistic perspective on the relationship between pyridoxal 5'-phosphate and inflammation. *Nutrition reviews*. 2013 Apr 1;71(4):239-44.
33. Parra M, Stahl S, Hellmann H. Vitamin B6 and its role in cell metabolism and physiology. *Cells*. 2018 Jul;7(7):84.